Shares of Cogent Biosciences were higher after the company disclosed what it called positive top-line results from a recent trial of its treatment for certain types of mastocytosis, a rare disorder in ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Upadacitinib 15 mg — but not 7.5 mg — alongside a glucocorticoid taper demonstrated superior efficacy to placebo with a ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging ...

Perovskite Solar Cells Market is Segmented by Type (Rigid Module, Flexible Module), by Application (BIPV, Power Station, ...

This article explores the relationship between the immune system and cancer and outlines therapeutic strategies that leverage ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous ...

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...